EGFR and osteosarcoma: Specifically, the treatment of ononin induces apoptosis, inhibiting cell proliferation, invasion, migration, and metastasis via blocking MMP2/9 expression and EGFR-Erk1/2 pathways, which was further validated using biomarkers in human osteosarcoma MG-63 xenograft mice.